Combining Two Competing Cancer Drugs, Study Finds Rare 100% Response Rate
The American Society of Clinical Oncology wrapped its annual conference this week, going through the usual motions of presenting a lot of drugs that offer some added quality or extension of life to those suffering from a variety of as-yet incurable diseases. But buried deep in an AP story are a couple of promising headlines that seems worthy of more thorough review, including one treatment study where 100 percent of patients saw their cancer diminished by half. First of all, it seems pharmaceutical companies are moving away from the more cost-effective one-size-fits-all approach to drug development and embracing the long tail of cancer treatments, engineering drugs that only work for a small percentage of patients but that work very effectively within that group. Related ArticlesFirst Preventative Cancer Vaccine Demonstrated to Work in MiceHideous Rodent May Provide Cure For Cancer Lucky Pet Dogs Receive Experimental Cancer Treatments Before Their HumansTagsScience, Clay Dillow,...